Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Acq. announced
Appointed director
Inv. presentation
Midatech Pharma US Inc. (DARA) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/07/2015 4 Form 4 - Statement of changes in beneficial ownership of securities
12/07/2015 4 Lieberman Gail (Director) has filed a Form 4 on Midatech Pharma US Inc.
12/07/2015 4 Drutz David (Executive Chairman and CMO) has filed a Form 4 on Midatech Pharma US Inc.
12/07/2015 4 CLEMENT CHRISTOPHER G (CEO) has filed a Form 4 on Midatech Pharma US Inc.
12/07/2015 4 Heady Timothy James (Director) has filed a Form 4 on Midatech Pharma US Inc.
12/07/2015 4 Richardson Paul John (Director) has filed a Form 4 on Midatech Pharma US Inc.
12/07/2015 4 Tousley David L. (CFO) has filed a Form 4 on Midatech Pharma US Inc.
12/07/2015 4 Benharris David (Senior Vice President) has filed a Form 4 on Midatech Pharma US Inc.
Txns: Disposed/sold 10,000 options @ $5, valued at $50k
Disposed/sold 35,000 options @ $5.05, valued at $176.8k
Disposed/sold 30,000 options @ $2.9, valued at $87k
Disposed/sold 95,000 options @ $0.79, valued at $75.1k
Disposed/sold 35,000 options @ $0.69, valued at $24.2k
12/04/2015 8-K Quarterly results
12/02/2015 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "DARA BioSciences Announces Stockholder Approval of Merger with Midatech RALEIGH, NC -- – December 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC and certain other parties thereto. Pursuant to the merger agreement, upon completion of the contemplated merger, DARA will become a wholly owned subsidiary of Midatech. The merger remains subject to customary closing conditions and is expected to close in the next week. ..."
11/19/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/18/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/18/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/12/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/09/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/02/2015 425 Form 425 - Prospectuses and communications, business combinations
11/02/2015 10-Q Quarterly Report for the period ended September 30, 2015
11/02/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
11/02/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Third Quarter 2015 Results Record Revenues for Q3 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – November 2, 2015 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results. Third Quarter 2015 Financial Snapshot DARA reported net revenues of $1.181 million for the third quarter ended September 30, 2015 based on gross product sales in excess of $1.5 million, as compared to net revenues of $597.8 ..."
10/22/2015 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition
09/02/2015 4 Richardson Paul John (Director) has filed a Form 4 on DARA BioSciences, Inc.
09/02/2015 4 COCHRANE HAYWOOD D (Director) has filed a Form 4 on DARA BioSciences, Inc.
09/02/2015 4 Heady Timothy James (Director) has filed a Form 4 on DARA BioSciences, Inc.
09/02/2015 4 Lieberman Gail (Director) has filed a Form 4 on DARA BioSciences, Inc.
08/12/2015 10-Q Quarterly Report for the period ended June 30, 2015
08/12/2015 8-K Quarterly results
Docs: "DARA BioSciences Announces Second Quarter 2015 Results Record Revenues for Q2 Company Reaffirms 2015 full year Guidance of $3.7 Million in Net Revenues Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- – August 12 -- DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results. Second Quarter 2015 Financial Snapshot DARA reported net revenues of $990.8 thousand for the second quarter ended June 30, 2015 based on gross product sales in excess of $1.4 million, as compared to net revenues of $409.4 thousan..."
08/12/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
08/12/2015 425 Form 425 - Prospectuses and communications, business combinations
06/05/2015 425 Form 425 - Prospectuses and communications, business combinations
06/05/2015 425 Form 425 - Prospectuses and communications, business combinations
06/05/2015 425 Form 425 - Prospectuses and communications, business combinations
06/04/2015 425 Form 425 - Prospectuses and communications, business combinations
06/04/2015 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among DARA BioSciences, Inc., Midatech Pharma, PLC, Merlin Acquisition Sub, Inc., Duke Acquisition Sub, Inc. and Shareholder Representative Services, LLC",
"Form of Contingent Value Rights Agreement",
"Form of Voting Agreement",
"- DARA’s Commercial Organization Key Driver of Agreement - Combined Organization Provides Pipeline of Oncology Products for U.S. Commercialization"
06/04/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy